HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences
Monday, June 12, 2023
HanAll Biopharma and Daewoong Pharmaceutical have recently revealed plans to enhance their open collaboration approach through an investment in Vincere Biosciences.
The two companies have come together to collaborate on the development of small-molecule therapies for patients with Parkinson's disease. This collaboration will leverage their combined knowledge and resources to advance the development of effective and targeted therapies, ultimately improving the lives of individuals living with Parkinson's disease.
This strategic move not only facilitates discussions for potential collaborations in Parkinson's disease therapeutics but also acknowledges the significance of Vincere's artificial intelligence platform.
The investment in Vincere Biosciences demonstrates dedication to forging strategic collaborations, particularly during the crucial period of convergence between drug development and artificial intelligence. Together, this will make a positive impact on the lives of patients by addressing the unmet needs in this challenging medical condition.
